The Top 7 Dividend Stocks to Buy in 2024 to Build Lasting Wealth

investorplace.com Dive into the fundamental prospects of these stocks as they lead the charge in dividend yields and growth strategies In the changing environment of 2024, astute investors…

3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge

investorplace.com Pharmaceutical companies with a deep pipeline of new molecular candiadates that will driven growth Big money tends to flow from one sector to the other. During the pandemic,…

3 Blue-Chip Stocks That Will Beat Index Returns Over the Next 3 Years

investorplace.com It’s an established point that blue-chip stocks are an essential part of the portfolio. The exposure to blue-chips can differ based on the risk-taking ability of an…

Is Pfizer Stock, At A 9-Year Low, A Sell Amid The Search For Its Big Break?

investors.com stock is trading at a nine-year low as the drugmaker looks for its next big break after developing the first Covid vaccine with Germany's BioNTech (BNTX). Last month, the…

If You'd Invested $1,000 in Pfizer 5 Years Ago, Here's How Much You'd Have Today

finance.yahoo.com If you had bought $1,000 worth of Pfizer (NYSE: PFE) shares five years ago, how much would that be worth today? The answer will strike you as terrific or terrible: $840.…

The 3 Most Overlooked Stocks Set for a Triple-Digit Comeback

investorplace.com Discover the hidden gems primed for a solid rebound in health care, consumer discretionary behavior, and communication Hidden treasures sometimes go overlooked in the busy…

3 No-Brainer Stocks to Buy With $100 Right Now

finance.yahoo.com Volatility and short-term unpredictability are a few of the guarantees that Wall Street offers investors. Since the green flag waved in January 2020, all three major stock…

Is Pfizer Stock a Buy?

finance.yahoo.com Pfizer (NYSE: PFE) isn't exactly a hot stock right now. Since its massive run-up during the pandemic's height, built on hopes for its coronavirus vaccine, new sources of…

A two-decade bet on a biotech company turned into a roughly $8 billion windfall for investors in the Baker Bros. Advisors hedge fund after Pfizer bought Seagen

wsj.com A two-decade bet on a biotech company turned into a roughly $8 billion windfall for investors in the Baker Bros. Advisors hedge fund after Pfizer bought Seagen.

Sunday links: a shrinking pie

abnormalreturns.com Finance Franklin Templeton ($BEN) is moving aggressively beyond stocks and bonds. (wsj.com) How fast can Blackrock ($BLK) really grow earnings? (riabiz.com) How this hedge…

Two Brothers, a Big Biotech Bet and an $8 Billion Payout

wsj.com Investors in a hedge fund from Baker Bros. Advisors recently received one of the largest windfalls ever following Pfizer’s purchase of Seagen.